Dal Bo Michele, Gambirasi Marta, Vruzhaj Idris, Cecchin Erika, Pishdadian Abbas, Toffoli Giuseppe, Safa Amin
Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.
Department of Life Sciences, University of Trieste, 34127 Trieste, Italy.
Int J Mol Sci. 2025 May 22;26(11):4982. doi: 10.3390/ijms26114982.
Aging is characterized by a progressive deterioration in physiological function and an increased susceptibility to age-related diseases, such as cancer. Monoclonal antibodies (mAbs) constitute a novel therapeutic approach aimed at addressing aging mechanisms such as cellular senescence, inflammaging, and immunosenescence. This text presents an overview of mAb methods aimed at the markers of aging and their potential application in cancer treatment. The mAbs can be categorized into senolytics, senescence-associated secretory phenotype (SASP) neutralizers, and immune checkpoint inhibitors, each targeting fewer aging-related pathways relevant to cancer therapeutic enhancement than the last. Translating promising preclinical evidence into enhanced efficacy and safety in cancer therapy presents challenges, particularly in older populations. This study examines the therapeutic efficacy of mAbs in the treatment of cancer and age-related disorders, focusing on their current and future roles in oncology practice.
衰老的特征是生理功能逐渐衰退，以及对癌症等与年龄相关疾病的易感性增加。单克隆抗体（mAbs）构成了一种新型治疗方法，旨在解决细胞衰老、炎症衰老和免疫衰老等衰老机制。本文概述了针对衰老标志物的单克隆抗体方法及其在癌症治疗中的潜在应用。单克隆抗体可分为衰老细胞裂解剂、衰老相关分泌表型（SASP）中和剂和免疫检查点抑制剂，每一类针对的与癌症治疗增强相关的衰老相关途径都比上一类少。将有前景的临床前证据转化为癌症治疗中更高的疗效和安全性面临挑战，尤其是在老年人群体中。本研究考察了单克隆抗体在癌症和与年龄相关疾病治疗中的疗效，重点关注它们在肿瘤学实践中的当前和未来作用。
